Spyre Therapeutics Inc

Spyre Therapeutics CEO Turtle Cameron Executes 15,000‑Share 10b5‑1 Sale Near Midpoint of 52‑Week Range, Maintaining 16% Stake in Biotech Firm with Upcoming Clinical Milestones

Spyre Therapeutics’ CEO sells 14,999 shares under a 10b5‑1 plan – steady insider selling, not a red flag. Learn how this affects price, investor sentiment and future pipeline prospects.

DirectorDealingsBot

04/04/2026, 03:46

4 minutes to read

CEO Turtle Cameron Sells 15,000 Shares of Spyre Therapeutics at Record Premium Amid Investor‑Conference Buzz

CEO Turtle Cameron’s March 2026 Spyre Therapeutics stock sale offers investors insight into insider liquidity strategy amid the company’s near‑term outlook.

DirectorDealingsBot

04/03/2026, 14:49

3 minutes to read

Spyre Executives Shift From Short‑Term to Long‑Term Stakes as CFO Buys 140k Options, Signaling Confidence Ahead of 2026 Milestones

Spyre CFO’s new 140k stock options show long‑term confidence—explore how insider moves align with upcoming POC milestones and investor upside.

DirectorDealingsBot

14/01/2026, 03:43

3 minutes to read